Manufacturing & Packaging

The enhancement—which complements the CDMO’s adeno-associated viral vector services—will be utilized at the company’s advanced therapies site in Stevenage, UK.

The project features several enhancements, including a new 67,000 square-foot warehouse at its HQ.

The company also participated in the coalition’s pilot inspection program, making it the first CDMO to do so.

Although it still has to undergo the preclinical and clinical trial process, the DNA vaccine—which could be created in as little as six weeks—does not require the cold chain storage that mRNA jabs often demand.

The 86,000 square-foot Køge facility will be fully functional by 2027.

The facility will focus on furthering RNA and DNA-based therapies.

Even as pharma technology evolves, and payers argue over reimbursement practices throughout healthcare, drug wholesaling is a thriving business.

The CDMO will also be adding new equipment for the manufacture of oligonucleotides and peptides.

The parties’ combined portfolio help tackle the rising demand for advanced cell and gene therapies.

The pre-approval pertains to a solid oral dose product that the CDMO will manufacture for a global pharmaceutical company.

The San Antonio facility will be taking this biomanufacturing initiative by the end of Q3 2024.

The deal exponentially grows the CDMO’s biopharma capabilities.

In a transaction valued at $250 million, the deal makes Grünenthal the new owner of Movantik, which treats OIC in adult patients with chronic non-cancer pain.

Analyzing the divergent paths undertaken by small biotech and large pharma companies in drug development.

The financial commitment includes a pair of expansion plans occurring in the United States and Europe.

The 50,000 square-foot facility has the ability to handle various batch sizes and dosage forms.

The construction of 100,000 square-foot facility will boost the site's filling capacity to 140 million units per year.

New production line represents Rentschler Biopharma SE’s biggest investment in its 150-year history.

The merger combines the companies under the MedPharma name, creating a topical and transepithelial CDMO in the process.

The deal provides the CDMO with ownership of the Lexington facility, allowing for late-phase and commercial gene therapy development and manufacturing of a branded severe Hemophilia B product.

The CRDMO will contribute cell discovery services that will benefit clinical development of novel technologies.

Following the evaluation, the company will decide whether it wants to move forward with the IDMO’s automated, end-to-end, cell therapy manufacturing platform.

The company’s latest investment—featuring new cGMP suites at its Devens, MA plant—is valued at $30 million.

The North Carolina project adds 1.4 million square feet of dedicated production space for aseptic manufacturing and finished production processes.

The agreement will look to further develop cell and gene therapies for the treatment of hematological cancers.

The Hopewell facility—which will serve as the CDMO’s North American hub—is expected to help accelerate the cell and gene therapy delivery process.

The partnership will offer an end-to-end manufacturing solution for biopharma companies.

The acquisition of the 87,000 square-foot Camden, MD plant provides the CDMO with the ability to offer clinical and commercial non-viral aseptic fill-finish services on four fill lines.

The contract manufacturer financially committed over $107 million into the facility, which can reportedly handle large-scale manufacturing of active ingredients based on messenger ribonucleic acid.

The 53,000 square-foot facility is expected to become a Northeastern biotech hub, and will be home to various CGT services.